Mark Anthony Tyndall - 01 Jan 2026 Form 4 Insider Report for Keenova Therapeutics plc

Reporting relationship: EVP & CLO and Corp Sec
Issuer ticker: N/A
Reported as of: 01 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jan 2026, 18:04:26 UTC
Prior SEC filing: 04 Aug 2025
Next SEC filing: 26 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Mark Tyndall

Key filing fact

Mark Anthony Tyndall filed Form 4 for Keenova Therapeutics plc on 05 Jan 2026.

Key facts

This page summarizes Mark Anthony Tyndall's Form 4 filing for Keenova Therapeutics plc.
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Jan 2026, 18:04.

Change

Previous filing in this sequence was filed on 04 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001944622 Primary reporting owner

Tyndall Mark Anthony

Relationship: EVP & CLO and Corp Sec
Address: 440 ROUTE 22 EAST, SUITE 302, BRIDGEWATER
Signature: /s/ Mark Tyndall
Signature date: 05 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

No ticker transaction

Ordinary Shares

Options Exercise

Transaction value
Shares: +6,576
Change %: +178%
Price
Shares after: 10,274
Date: 01 Jan 2026
Ownership: Direct
Footnotes: F1

No ticker transaction

Ordinary Shares

Tax liability

Transaction value
Shares: -2,107
Change %: -21%
Price
Shares after: 8,167
Date: 01 Jan 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

No ticker transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -6,576
Change %: -13%
Price: $0.000000
Shares after: 46,031
Date: 01 Jan 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 6,576
Exercise price
Footnotes: F1, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU.

Footnote F2

The number of ordinary shares withheld to satisfy tax withholding obligations arising out the vesting of RSUs is based on a percentage and did not take into account any market value as the Issuer's ordinary shares are not listed or quoted on a recognized trading market.

Footnote F3

On February 2, 2024, the Reporting Person was granted 16,413 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Outstanding RSUs were subsequently adjusted as described in footnote 4 below.

Footnote F4

Reflects that the Reporting Person received 8,836 additional RSUs resulting from the adjustment of the RSUs held by the Reporting Person immediately prior to the separation of Par Health, Inc. ("Par Health") from the Issuer on November 10, 2025, pursuant to the terms of the Employee Matters Agreement by and between the Issuer and Par Health.

SEC remarks

This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.